焦

2022年7月18日

信息:*必選字段建議規則，如果CY23被采用，將增加在醫院門診完成的Focal One HIFU手術的醫療保險支付，法國裏昂，2022年7月18日- EDAP TMS SA(納斯達克:機器人能量療法的全球領導者EDAP(“公司”)今天宣布，美國醫療保險和醫療補助服務中心(CMS)已經發布了其2023年(CY23年)擬議的門診前瞻性支付係統(OPPS)報銷規則。對於在門診進行病灶1級HIFU前列腺消融術的醫院，擬議的規則將把報銷等級從目前的APC等級5提高到門診支付等級6。這將導致醫院對醫療保險患者進行HIFU(高強度聚焦超聲)手術的報銷增加到全國平均每次手術8,711美元(根據當地工資指數調整)，而目前全國平均每次手術的報銷為4,506美元(根據當地工資指數調整)。APC級別提高到6級對醫療保險以外的患者有積極的影響，因為許多商業支付方已經開始為其成員支付局灶性HIFU。商業支付和獲取政策受到醫療保險政策和報銷決定的影響。EDAP美國首席執行官Ryan Rhodes表示:“這一提議的規則反映了HIFU在前列腺護理連續體中的適當價值，特別是相對於更多的侵入性治療，如根治性手術或放射治療。如果最終規則維持這裏提出的報銷水平的增長，我們相信這將是一個重要的催化劑，加速機構及其患者獲得局灶性HIFU的好處。”對擬議規則的評論截止日期為9月30日，最終規則預計將於11月出台。最終規則中的政策和支付費率一般將於2023年1月1日生效。 About EDAP TMS SA A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com , us.hifu-prostate.com and www.focalone.com. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Company Contact